Advertisement

Topics

Latest Immunology NewsRSS

16:33 EST 18th December 2018 | BioPortfolio

$ONCS Announces Publication of New Research in the Journal Immunity Highlighting the Role of IL-12 in Anti-PD-1 Therapies with TAVO™ Directly Activating TILs in Patients https://www.prnewswire.com/news-releases/oncosec-announces-publication-of-new-resea

$ONCS Announces Publication of New Research in the Journal Immunity Highlighting the Role of IL-12 in Anti-PD-1 Therapies with TAVO™ Directly Activating TILs in Patients https://www.prnewswire.com/news-releases/oncosec-announces-publication-of-new-research-in-the-journal-immunity-highlighting-the-role-of-il-12-in-anti-pd-1-therapies-with-tavo-directly-activating-tils-in-patients-300767865....

Pfizer taps Seattle-based Kineta in immunotherapy deal

The pharma, which trails other rivals in immuno-oncology, aims to uncover new ways of boosting anti-tumor immune responses through the partnership.

HIV Vaccine in Monkeys Suggests Human Vaccine on the Horizon

So far, a vaccine for HIV has been elusive. However, researchers with Scripps Research Institute recently published positive data about its HIV vaccine in the journal Immunity that suggests one might be on the horizon.

. @AstellasUS boosts #Cancer #immunotherapy pipeline with @PotenzaTx acquisition: http://ow.ly/8c2n30n123c 

. @AstellasUS boosts #Cancer #immunotherapy pipeline with @PotenzaTx acquisition: http://ow.ly/8c2n30n123c 

Immunotherapy Could Have Role in Frontline HCC

Michael J. Pishvaian, MD, PhD, discusses the impact of immunotherapy in the treatment landscape of hepatocellular carcinoma. 

. @AstellasUS Acquires Collaboration Partner @PotenzaTx, Adding #Cancer Immunotherapy Programs: http://ow.ly/8c2n30n123c pic.twitter.com/VwhsyoXvHW

. @AstellasUS Acquires Collaboration Partner @PotenzaTx, Adding #Cancer Immunotherapy Programs: http://ow.ly/8c2n30n123c  pic.twitter.com/VwhsyoXvHW

Astellas Acquires Collaboration Partner Potenza, Adding Cancer Immunotherapy Programs

Astellas Pharma has acquired Potenza Therapeutics for up to $404.7 million in a deal that bolsters the buyer’s cancer immunotherapy pipeline—more than three years after the companies launched an immuno-oncology collaboration that has produced two Phase I candidates and a third candidate bound for the clinic. Headquartered in Cambridge, MA, Potenza is a four-year-old cancer […] The post A...

#Immunotherapy Offers Hope to Neurofibromatosis Type 1 Brain Tumor Patients: http://ow.ly/pDxH30mWGKi pic.twitter.com/zBpHeeQ4cM

#Immunotherapy Offers Hope to Neurofibromatosis Type 1 Brain Tumor Patients: http://ow.ly/pDxH30mWGKi  pic.twitter.com/zBpHeeQ4cM

Expert Highlights Utility of PD-L1 to Select Immunotherapy in NSCLC

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Amgen scraps deal with Advaxis to develop cancer immunotherapy ADXS-NEO https://www.firstwordpharma.com/node/1611622  $AMGN $ADXS

Amgen scraps deal with Advaxis to develop cancer immunotherapy ADXS-NEO https://www.firstwordpharma.com/node/1611622  $AMGN $ADXS

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer

Results from a real-world study1 support a recent update to the ESMO guidelines2 recommending nintedanib (Vargatef®) plus docetaxel following first-line chemotherapy (+/- immunotherapy) in advanced NSCLC of adenocarcinoma histology Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-intervent...

Dragonfly Therapeutics Announces $CELG In-license of First Two TriNKET™ Immunotherapy Drug Candidates https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-celgene-in-license-of-first-two-trinket-immunotherapy-drug-candidates-3007650

Dragonfly Therapeutics Announces $CELG In-license of First Two TriNKET™ Immunotherapy Drug Candidates https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-celgene-in-license-of-first-two-trinket-immunotherapy-drug-candidates-300765057.html …

Very interesting work by @MarcoLDavila et al https://www.nature.com/articles/d41586-018-07581-w … Catecholamines fuels a cytokine storm during #immunotherapy; Old hypertension drug metyrosine could treat CRS https://www.nature.com/articles/s41586-018

Very interesting work by @MarcoLDavila et al https://www.nature.com/articles/d41586-018-07581-w … Catecholamines fuels a cytokine storm during #immunotherapy; Old hypertension drug metyrosine could treat CRS https://www.nature.com/articles/s41586-018-0774-y …

Early Career Profile: Chantal Hargreaves

Chantal Hargreaves is a postdoctoral scientist funded through the Oxford BRC’s Gastroenterology and Mucosal Immunity Theme. Working in the lab of Clinical Immunologist Dr Smita Patel at the John Radcliffe Hospital, Chantal is conducting research into how genetic variations impact on the immune system. “Smita’s patients are born with genetic ‘errors’ in their DNA, which ... Read more

Pfizer Transfers 100 Jobs to La Jolla Oncology Site as It Closes Facility in South San Francisco

Pfizer’s La Jolla cancer research center is set to grow by about 100 people. The pharma giant is transferring employees from a recently shuttered South San Francisco immunology site to bolster the work conducted near San Diego.

Vaccinex Preclinical Data Published in Cancer Immunology Research

Vaccinex (Nasdaq:VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces preclinical data on the company’s anti-SEMA4D, in combination with checkpoint inhibitors, was published online...

Before he passed away in October, philanthropist Paul Allen was laying plans for a major contribution to expand the study of human immunology. https://buff.ly/2UAHFel 

Before he passed away in October, philanthropist Paul Allen was laying plans for a major contribution to expand the study of human immunology. https://buff.ly/2UAHFel 

$VCNX Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research https://globenewswire.com/news-release/2018/12/12/1665908/0/en/Preclinical-Data-on-Vaccinex-Inc-Anti

$VCNX Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research https://globenewswire.com/news-release/2018/12/12/1665908/0/en/Preclinical-Data-on-Vaccinex-Inc-Anti-SEMA4D-Monoclonal-Antibody-in-Combination-with-Checkpoint-Inhibitors-Published-in-Cancer-Immunology-Research.html …

$ADRO Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2380389 …

$ADRO Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2380389 …

Checkmate Pharmaceuticals Announces CEO Transition and $22 Million Financing

Expanded Leadership Team and Funding Supports Advancement of Clinical Development of Checkmate’s TLR9 Agonist, CMP-001 Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, has appointed Barry Labinger as President and CEO. Arthur M. Krieg, MD, Checkmate’s fou...

With a gift from the late Paul Allen, his philanthropy launches ambitious plan to probe human immunology

Before he passed away in October, philanthropist Paul Allen was laying plans for a major contribution to expand the study of human immunology.

International consortium reports that slow-growing brain tumor arising in patients affected by neurofibromatosis type 1 may be vulnerable to #immunotherapy: http://ow.ly/pDxH30mWGKi 

International consortium reports that slow-growing brain tumor arising in patients affected by neurofibromatosis type 1 may be vulnerable to #immunotherapy: http://ow.ly/pDxH30mWGKi 

Former Eli Lilly Executive to Head New Immunology Division of the Allen Institute

Microsoft co-founder Paul Allen set aside $125 million to fund a new division at a scientific institute he founded to focus on understanding the immune system. This morning, it was reported that the Allen Institute is expanding.

Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research

ROCHESTER, N.Y., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces preclinical data on the company’s anti-SEMA4D, i...

Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity

BERKELEY, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the publication of a peer-reviewed paper in Cell Reports authored by Aduro scientists and Novartis collaborators as part of their ongoing research to study intratumoral stimulator of interferon genes (STING) pathway activation as a potential therapeutic approach for the treatment of cancer. In...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Immunology market research data and corporate reports here